Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan, 410008, People's Republic of China.
EPMA J. 2013 Jan 22;4(1):2. doi: 10.1186/1878-5085-4-2.
Cancer is a complex disease that causes the alterations in the levels of gene, RNA, protein and metabolite. With the development of genomics, transcriptomics, proteomics and metabolomic techniques, the characterisation of key mutations and molecular pathways responsible for tumour progression has led to the identification of a large number of potential targets. The increasing understanding of molecular carcinogenesis has begun to change paradigms in oncology from traditional single-factor strategy to multi-parameter systematic strategy. The therapeutic model of cancer has changed from adopting the general radiotherapy and chemotherapy to personalised strategy. The development of predictive, preventive and personalised medicine (PPPM) will allow prediction of response with substantially increased accuracy, stratification of particular patient groups and eventual personalisation of medicine. The PPPM will change the approach to tumour diseases from a systematic and comprehensive point of view in the future. Patients will be treated according to the specific molecular profiles that are found in the individual tumour tissue and preferentially with targeted substances, if available.
癌症是一种复杂的疾病,会导致基因、RNA、蛋白质和代谢物水平的改变。随着基因组学、转录组学、蛋白质组学和代谢组学技术的发展,对导致肿瘤进展的关键突变和分子途径的特征描述,已经确定了大量潜在的靶点。对分子致癌作用的认识不断加深,已经开始使肿瘤学中的传统单一因素策略向多参数系统策略转变。癌症的治疗模式已经从采用普通的放疗和化疗转变为个性化策略。预测性、预防性和个体化医学(PPPM)的发展将极大地提高预测反应的准确性,对特定患者群体进行分层,并最终实现个体化医疗。未来,PPPM 将从系统和全面的角度改变肿瘤疾病的治疗方法。根据在个体肿瘤组织中发现的特定分子谱,并在有靶向物质的情况下,对患者进行优先治疗。